Document:

EX-4.4

 Exhibit 4.4 
 AXIS CAPITAL HOLDINGS LIMITED 
 2007 LONG-TERM EQUITY COMPENSATION PLAN

 As Amended and Restated May 2012 
 SECTION 1. Purpose. The purpose of this AXIS Capital Holdings Limited 2007 Long-Term Equity Compensation Plan is to promote the interests of AXIS Capital Holdings Limited, a company organized
and existing under Bermuda law, and its stockholders by (a) attracting and retaining exceptional directors, officers, employees and consultants (including prospective directors, officers, employees and consultants) of the Company (as defined
below) and its Affiliates (as defined below) and (b) enabling such individuals to participate in the long-term growth and financial success of the Company. 
 SECTION 2. Definitions. As used herein, the following terms shall have the meanings set forth below: 
 “Affiliate” means (a) any entity that, directly or indirectly, is controlled by, controls or is under common control with, the Company and (b) any entity in which the Company
has a significant equity interest, in either case as determined by the Committee. 
 “Award” means any award
that is permitted under Section 6 and granted under the Plan. 
 “Award Agreement” means any written
agreement, contract or other instrument or document evidencing any Award, which may, but need not, require execution or acknowledgment by a Participant. 
 “Board” means the Board of Directors of the Company. 

“Change of Control” shall (a) have the meaning set forth in an Award Agreement or (b) if there is no
definition set forth in an Award Agreement, will be deemed to have occurred as of the first day any of the following events occurs: 
 (i) Any Person is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing 50% or more of the
combined voting power of the Company’s then outstanding voting securities entitled to vote generally in the election of directors (the “Outstanding Company Voting Securities”); provided, however, that for purposes
of this subsection (i), the following acquisitions shall not constitute a Change in Control: (A) any acquisition directly from the Company, (B) any acquisition by the Company, (C) any acquisition by any employee benefit plan (or
related trust) sponsored or maintained by the Company or any Affiliate, or (D) any acquisition by any entity pursuant to a transaction which complies with clauses (A), (B) and (C) of paragraph (iii) below; 

(ii) Individuals who, as of the Effective Date, constitute the Board (hereinafter referred to as the “Incumbent Board”)
cease for any reason to constitute at least a majority of the Board; provided however, that any individual becoming a director subsequent to the date herein whose election, or nomination for election by the Company’s stockholders, was approved
by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered a member of the Incumbent Board, excluding any individual whose initial assumption of office occurs as a result of an actual or threatened
election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of a Person other than the Board; 

  
 1 

 (iii) Consummation of a reorganization, merger, share exchange, amalgamation,
recapitalization, consolidation or similar transaction by and among the Company and another Person, including, for this purpose, a transaction as a result of which another Person owns the Company or all or substantially all of the Company’s
assets, either directly or through one or more subsidiaries (a “Business Combination”), in each case, unless, following such Business Combination, (A) all or substantially all of the individuals and entities who were the
beneficial owners, respectively, of the Outstanding Company Voting Securities immediately prior to such Business Combination beneficially own, directly or indirectly, more than 50% of the combined voting power of the then outstanding voting
securities entitled to vote generally in the election of directors (or equivalent management personnel) of the Person resulting from such Business Combination or that, as a result of such Business Combination, owns the Company or all or
substantially all of the Company’s assets, either directly or through one or more subsidiaries, in substantially the same proportions as their ownership of the Outstanding Company Voting Securities immediately prior to such Business
Combination; (B) no Person (excluding any Person resulting from such Business Combination, or that, as a result of such Business Combination, owns the Company or all or substantially all of the Company’s assets, either directly or through
one or more subsidiaries, or any employee benefit plan (or related trust) of the foregoing) beneficially owns, directly or indirectly, 50% or more of the then outstanding shares of common stock or the combined voting power of the then outstanding
voting securities entitled to vote generally in the election of directors (or equivalent management personnel) of the Person resulting from such Business Combination or that, as a result of such Business Combination, owns the Company or all or
substantially all of the Company’s assets, either directly or through one or more subsidiaries, except to the extent that such ownership existed with respect to the Company prior to the Business Combination; and (C) at least a majority of
the members of the board of directors (or equivalent management personnel) of the Person resulting from such Business Combination or that, as a result of such Business Combination, owns the Company or all or substantially all of the Company’s
assets, either directly or through one or more subsidiaries, were members of the Incumbent Board at the time of the execution of the initial agreement, or of the action of the board, pursuant to which such Business Combination is effected or
approved; or 
 (iv) Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company or the
sale or other disposition of all or substantially all of the Company’s assets. 
 “Code” means the
Internal Revenue Code of 1986, as amended from time to time, and the regulations promulgated thereunder. 

“Committee” means the Compensation Committee of the Board, or such other committee of the Board as may be designated by
the Board to administer the Plan. 
 “Company” means AXIS Capital Holdings Limited and any successor (whether
direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business or assets of AXIS Capital Holdings Limited. 

  
 2 

 “Disability” shall have the meaning ascribed to such term in the employee
health care plan maintained by the Company, or if no such plan exists, at the discretion of the Committee. 
 “Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute thereto. 
 “Exercise
Price” means (a) in the case of Options, the price specified in the applicable Award Agreement as the price-per-Share at which Shares may be purchased pursuant to such Option or (b) in the case of SARs, the price specified in the
applicable Award Agreement as the reference price-per-Share used to calculate the amount payable to the Participant. 

“Fair Market Value” means (a) with respect to any property other than Shares, the fair market value of such
property determined by such methods or procedures as shall be established from time to time by the Committee and (b) with respect to the Shares, as of any date, (i) the closing per share sales price of the Shares (A) as reported by
the NYSE for such date or (B) if the Shares are listed on any other national stock exchange, as reported on the stock exchange composite tape for securities traded on such stock exchange for such date or, with respect to each of
clauses (A) and (B), if there were no sales on such date, on the closest preceding date on which there were sales of Shares or (ii) in the event there shall be no public market for the Shares on such date, the fair market value of the
Shares as determined in good faith by the Committee. 
 “Incentive Stock Option” means an option to purchase
Shares from the Company that (a) is granted under Section 6(b) and (b) is intended to qualify for special Federal income tax treatment pursuant to Sections 421 and 422 of the Code, as now constituted or subsequently amended, or
pursuant to a successor provision of the Code, and which is so designated in the applicable Award Agreement. 

“IRS” means the Internal Revenue Service or any successor thereto and includes the staff thereof. 

“NYSE” means the New York Stock Exchange or any successor thereto. 

“Non-Employee Director” means a member of the Board who is neither (a) an employee of the Company nor (b) an
employee of any Affiliate. 
 “Nonqualified Stock Option” means an option to purchase Shares from the Company
that (a) is granted under Section 6(b) and (b) is not an Incentive Stock Option. 
 “Option”
means an Incentive Stock Option or a Nonqualified Stock Option or both, as the context requires. 

“Participant” means any director, officer, employee or consultant (including any prospective director, officer, employee
or consultant) of the Company or its Affiliates who is eligible for an Award under Section 5 and who is selected by the Committee to receive an Award under the Plan or who receives a Substitute Award pursuant to Section 4(c). 

“Performance Criteria” means the criterion or criteria that the Committee shall select for purposes of establishing a
Performance Goal for a Performance Period with respect to any Performance Unit under the Plan. 

  
 3 

 “Performance Goal” means, for a Performance Period, the one or more goals
established by the Committee for the Performance Period based upon the Performance Criteria. 
 “Performance
Period” means the one or more periods of time as the Committee may select over which the attainment of one or more Performance Goals will be measured for the purpose of determining a Participant’s right to and the payment of a
Performance Unit. 
 “Performance Unit” means an Award under Section 6(e) that has a value set by the
Committee (or that is determined by reference to a valuation formula specified by the Committee or the Fair Market Value of Shares), which value may be paid to the Participant by delivery of such property as the Committee shall determine, including
without limitation, cash or Shares, or any combination thereof, upon achievement of such Performance Goals during the relevant Performance Period as the Committee shall establish at the time of such Award or thereafter. 

“Person” shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections
13(d) and 14(d) thereof, including a “group” as defined in Section 13(d) thereof. 
 “Plan”
means this AXIS Capital Holdings Limited 2007 Long-Term Equity Compensation Plan, as in effect from time to time. 

“Restricted Share” means a Share delivered under the Plan that is subject to certain transfer restrictions, forfeiture
provisions and/or other terms and conditions specified herein and in the applicable Award Agreement. 

“Retirement” shall (a) have the meaning set forth in an Award Agreement or (b) if there is no definition set
forth in an Award Agreement, means: 
 (i) for an employee, such employee’s termination of employment with the Company and
its Affiliates but only if either (A) such termination shall have occurred on or after the date on which he or she shall have attained age 60 and prior to such termination such employee shall have completed 5 years of continuous employment with
the Company and its Affiliates or (B) the Committee by affirmative action determines such termination shall constitute a Retirement for purposes of the Plan; and 
 (ii) for a director, such director’s termination of service with the Company and its Affiliates but only if either (A) such termination shall have occurred on or after the date on which he or
she shall have attained age 60 and prior to such termination such director shall have completed 5 years of continuous employment with the Company and its Affiliates or (B) the Board by affirmative action determines such termination shall
constitute a Retirement for purposes of the Plan. 
 Consultants shall not be eligible for Retirement hereunder. 

“RSU” means a restricted stock unit Award that is designated as such in the applicable Award Agreement and that
represents an unfunded and unsecured promise to deliver Shares, cash, other securities, other Awards or other property in accordance with the terms of the applicable Award Agreement. 

“Rule 16b-3” means Rule 16b-3 as promulgated and interpreted by the SEC under the Exchange Act or any
successor rule or regulation thereto as in effect from time to time. 

  
 4 

 “SAR” means a stock appreciation right Award that represents an unfunded
and unsecured promise to deliver Shares, cash, other securities, other Awards or other property equal in value to the excess, if any, of the Fair Market Value per Share over the Exercise Price per Share of the SAR, subject to the terms of the
applicable Award Agreement. 
 “SEC” means the Securities and Exchange Commission or any successor thereto and
shall include the staff thereof. 
 “Shares” means shares of common stock of the Company, par value $0.0125 per
share, or such other securities of the Company (a) into which such shares shall be changed by reason of a recapitalization, merger, consolidation, split-up, combination, exchange of shares or other similar transaction or (b) as may be
determined by the Committee pursuant to Section 4(b). 
 “Subsidiary” means any entity in which the
Company, directly or indirectly, possesses 50% or more of the total combined voting power of all classes of its stock. 

“Substitute Awards” shall have the meaning specified in Section 4(c). 

SECTION 3. Administration. (a) Composition of Committee. The Plan shall be administered by the Committee, which shall be
composed of one or more directors, as determined by the Board; provided that, to the extent necessary to comply with the rules of the NYSE and Rule 16b-3 and any other applicable laws or rules, the Committee shall be composed of two or more
directors, all of whom shall be Non-Employee Directors and all of whom shall (i) meet the independence requirements of the NYSE and (ii) qualify as “Non-Employee Directors” under Rule 16b-3. 

(b) Authority of Committee. Subject to the terms of the Plan and applicable law, and in addition to other express powers and
authorizations conferred on the Committee by the Plan, the Committee shall have sole and plenary authority to administer the Plan, including, but not limited to, the authority to (i) designate Participants, (ii) determine the type or types
of Awards to be granted to a Participant, (iii) determine the number of Shares to be covered by, or with respect to which payments, rights or other matters are to be calculated in connection with, Awards, (iv) determine the terms and
conditions of any Awards, (v) determine the vesting schedules of Awards and, if certain performance criteria must be attained in order for an Award to vest or be settled or paid, establish such performance criteria and certify whether, and to
what extent, such performance criteria have been attained, (vi) determine whether, to what extent and under what circumstances Awards may be settled or exercised in cash, Shares, other securities, other Awards or other property, or canceled,
forfeited or suspended and the method or methods by which Awards may be settled, exercised, canceled, forfeited or suspended, (vii) determine whether, to what extent and under what circumstances cash, Shares, other securities, other Awards,
other property and other amounts payable with respect to an Award shall be deferred either automatically or at the election of the holder thereof or of the Committee, (viii) interpret, administer, reconcile any inconsistency in, correct
any default in and supply any omission in, the Plan and any instrument or agreement relating to, or Award made under, the Plan, (ix) establish, amend, suspend or waive such rules and regulations and appoint such agents as it shall deem
appropriate for the proper administration of the Plan, (x) accelerate the vesting or exercisability of, payment for or lapse of restrictions on, Awards, (xi) amend an outstanding Award or grant a replacement

  
 5 

 
Award for an Award previously granted under the Plan if, in its sole discretion, the Committee determines that (A) the tax consequences of such Award to the Company or the Participant differ
from those consequences that were expected to occur on the date the Award was granted or (B) clarifications or interpretations of, or changes to, tax law or regulations permit Awards to be granted that have more favorable tax consequences than
initially anticipated and (xii) make any other determination and take any other action that the Committee deems necessary or desirable for the administration of the Plan. 
 (c) Committee Decisions. Unless otherwise expressly provided in the Plan, all designations, determinations, interpretations and other decisions under or with respect to the Plan or any Award shall
be within the sole and plenary discretion of the Committee, may be made at any time and shall be final, conclusive and binding upon all persons, including the Company, any Affiliate, any Participant, any holder or beneficiary of any Award and any
stockholder. 
 (d) Indemnification. No member of the Board, the Committee or any employee of the Company (each such
person, a “Covered Person”) shall be liable for any action taken or omitted to be taken or any determination made in good faith with respect to the Plan or any Award hereunder. Each Covered Person shall be indemnified and held harmless by
the Company against and from (i) any loss, cost, liability or expense (including attorneys’ fees) that may be imposed upon or incurred by such Covered Person in connection with or resulting from any action, suit or proceeding to which such
Covered Person may be a party or in which such Covered Person may be involved by reason of any action taken or omitted to be taken under the Plan or any Award Agreement and (ii) any and all amounts paid by such Covered Person, with the
Company’s approval, in settlement thereof, or paid by such Covered Person in satisfaction of any judgment in any such action, suit or proceeding against such Covered Person; provided that the Company shall have the right, at its own expense, to
assume and defend any such action, suit or proceeding, and, once the Company gives notice of its intent to assume the defense, the Company shall have sole control over such defense with counsel of the Company’s choice. The foregoing right of
indemnification shall not be available to a Covered Person to the extent that a court of competent jurisdiction in a final judgment or other final adjudication, in either case not subject to further appeal, determines that the acts or omissions of
such Covered Person giving rise to the indemnification claim resulted from such Covered Person’s bad faith, fraud or willful criminal act or omission or that such right of indemnification is otherwise prohibited by law or by the Company’s
Memorandum of Association or Bye-Laws. The foregoing right of indemnification shall not be exclusive of any other rights of indemnification to which Covered Persons may be entitled under the Company’s Memorandum of Association or Bye-Laws, as a
matter of law, or otherwise, or any other power that the Company may have to indemnify such persons or hold them harmless. 

(e) Delegation of Authority to Senior Officers. The Committee may delegate, on such terms and conditions as it determines in its
sole and plenary discretion, to one or more senior officers of the Company the authority to make grants of Awards to officers (other than officers subject to Section 16 of the Exchange Act), employees and consultants of the Company and its
Affiliates (including any prospective officer, employee or consultant) and all necessary and appropriate decisions and determinations with respect thereto; provided, however, that the cash settlement of Awards may only be permitted with the express
written consent of the Committee. 

  
 6 

 (f) Awards to Non-Employee Directors. Notwithstanding anything to the contrary
contained herein, the Compensation Committee may, in its sole and plenary discretion, at any time and from time to time, grant Awards to Non-Employee Directors. 
 SECTION 4. Shares Available for Awards. (a) Shares Available. Subject to adjustment as provided in Section 4(b), the aggregate number of Shares that may be delivered pursuant to Awards
granted under the Plan shall be 15,000,000. The maximum number of Shares that may be delivered pursuant to Incentive Stock Options granted under the Plan shall be 15,000,000 (“Plan Shares”). If, after the effective date of the Plan, any
Award granted under the Plan is forfeited, or otherwise expires, terminates or is canceled without the delivery of Shares, then the Shares covered by such forfeited, expired, terminated or canceled Award shall again become available to be delivered
pursuant to Awards under the Plan. If Shares issued upon exercise, vesting or settlement of an Award, or Shares owned by a Participant (which are not subject to any pledge or other security interest), are surrendered or tendered to the Company in
payment of the Exercise Price of an Award or any taxes required to be withheld in respect of an Award, in each case, in accordance with the terms and conditions of the Plan and any applicable Award Agreement, such surrendered or tendered Shares
shall again become available to be delivered pursuant to Awards under the Plan; provided, however, that in no event shall such Shares increase the number of Shares that may be delivered pursuant to Incentive Stock Options granted under
the Plan. Notwithstanding any provision of the Plan to the contrary, the aggregate number of Shares subject to Awards (i) granted in the form of “other equity-based or equity-related Awards” pursuant to Section 6(a)(vi) and
(ii) with respect to which restrictions may be waived or lapsed pursuant to Section 7(b), other than in connection with a Change of Control or in the case of the death, Disability or Retirement of a Participant, shall not exceed 10% of the
Plan Shares. 
 (b) Adjustments for Changes in Capitalization and Similar Events. (i) In the event of any extraordinary
dividend or other extraordinary distribution (whether in the form of cash, Shares, other securities or other property), recapitalization, stock split, reverse stock split, split-up or spin-off, the Committee shall, in order to preserve the value of
the Award and in the manner determined by the Committee, adjust any or all of (A) the number of Shares or other securities of the Company (or number and kind of other securities or property) with respect to which Awards may be granted,
including (1) the aggregate number of Shares that may be delivered pursuant to Awards granted under the Plan (including pursuant to Incentive Stock Options), as provided in Section 4(a) and (2) the maximum number of Shares or other
securities of the Company (or number and kind of other securities or property) with respect to which Awards may be granted to any Participant in any fiscal year of the Company and (B) the terms of any outstanding Award, including (1) the
number of Shares or other securities of the Company (or number and kind of other securities or property) subject to outstanding Awards or to which outstanding Awards relate and (2) the Exercise Price, if applicable, with respect to any Award.

 (ii) In the event that the Committee determines that any reorganization, merger, consolidation, combination, repurchase or
exchange of Shares or other securities of the 

  
 7 

 
Company, issuance of warrants or other rights to purchase Shares or other securities of the Company, or other similar corporate transaction or event affects the Shares such that an adjustment is
determined by the Committee in its discretion to be appropriate or desirable, then the Committee may (A) in such manner as it may deem equitable or desirable, adjust any or all of (1) the number of Shares or other securities of the Company
(or number and kind of other securities or property) with respect to which Awards may be granted, including (X) the aggregate number of Shares that may be delivered pursuant to Awards granted under the Plan, as provided in Section 4(a) and
(Y) the maximum number of Shares or other securities of the Company (or number and kind of other securities or property) with respect to which Awards may be granted to any Participant in any fiscal year of the Company and (2) the terms of
any outstanding Award, including (X) the number of Shares or other securities of the Company (or number and kind of other securities or property) subject to outstanding Awards or to which outstanding Awards relate and (Y) the Exercise
Price, if applicable, with respect to any Award, (B) if deemed appropriate or desirable by the Committee, make provision for a cash payment to the holder of an outstanding Award in consideration for the cancellation of such Award, including, in
the case of an outstanding Option or SAR, a cash payment to the holder of such Option or SAR in consideration for the cancellation of such Option or SAR in an amount equal to the excess, if any, of the Fair Market Value (as of a date specified by
the Committee) of the Shares subject to such Option or SAR over the aggregate Exercise Price of such Option or SAR and (C) if deemed appropriate or desirable by the Committee, cancel and terminate any Option or SAR having a per Share Exercise
Price equal to, or in excess of, the Fair Market Value of a Share subject to such Option or SAR without any payment or consideration therefor. 
 (c) Substitute Awards. Awards may, in the discretion of the Committee, be granted under the Plan in assumption of, or in substitution for, outstanding awards previously granted by the Company or
any of its Affiliates or a company acquired by the Company or any of its Affiliates or with which the Company or any of its Affiliates combines (such Awards, “Substitute Awards”). The number of Shares underlying any Substitute Awards shall
be counted against the aggregate number of Shares available for Awards under the Plan; provided, however, that Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding awards previously granted by an entity
that is acquired by the Company or any of its Affiliates or with which the Company or any of its Affiliates combines shall not be counted against the aggregate number of Shares available for Awards under the Plan; provided further, however, that
Substitute Awards issued in connection with the assumption of, or in substitution for, outstanding stock options intended to qualify for special tax treatment under Sections 421 and 422 of the Code that were previously granted by an entity that is
acquired by the Company or any of its Affiliates or with which the Company or any of its Affiliates combines shall be counted against the aggregate number of Shares available for Incentive Stock Options under the Plan. Notwithstanding anything in
this Section 4(c) to the contrary, without the approval of the shareholders of the Company, in no event may any Option or SAR granted under the Plan be (i) amended to decrease the Exercise Price thereof, or (ii) cancelled in exchange
for cash or the grant of Substitute Awards to the extent that such grant would result in an assumption of, or substitution for, an outstanding Option or SAR previously granted by the Company or any of its Affiliates, that would have the effect of
reducing the Exercise Price of such outstanding Option or SAR. 

  
 8 

 (d) Sources of Shares Deliverable Under Awards. Any Shares delivered pursuant to an
Award may consist, in whole or in part, of authorized and unissued Shares or of treasury Shares. 
 SECTION 5.
Eligibility. Any director, officer, employee or consultant (including any prospective director, officer, employee or consultant) of the Company or any of its Affiliates shall be eligible to be designated a Participant. 

SECTION 6. Awards. (a) Types of Awards. Awards may be made under the Plan in the form of (i) Options,
(ii) SARs, (iii) Restricted Shares, (iv) RSUs, (v) Performance Units and (vi) other equity-based or equity-related Awards that the Committee determines are consistent with the purpose of the Plan and the interests of the
Company. Awards may be granted in tandem with other Awards. No Incentive Stock Option (other than an Incentive Stock Option that may be assumed or issued by the Company in connection with a transaction to which Section 424(a) of the Code
applies) may be granted to a person who is ineligible to receive an Incentive Stock Option under the Code. 
 (b)
Options. (i) Grant. Subject to the provisions of the Plan, the Committee shall have sole and plenary authority to determine the Participants to whom Options shall be granted, the number of Shares to be covered by each Option,
whether the Option will be an Incentive Stock Option or a Nonqualified Stock Option and the conditions and limitations applicable to the vesting and exercise of the Option. In the case of Incentive Stock Options, the terms and conditions of such
grants shall be subject to and comply with such rules as may be prescribed by Section 422 of the Code and any regulations related thereto, as may be amended from time to time. All Options granted under the Plan shall be Nonqualified Stock
Options unless the applicable Award Agreement expressly states that the Option is intended to be an Incentive Stock Option. If an Option is intended to be an Incentive Stock Option, and if for any reason such Option (or any portion thereof) shall
not qualify as an Incentive Stock Option, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a Nonqualified Stock Option appropriately granted under the Plan; provided that such Option (or portion
thereof) otherwise complies with the Plan’s requirements relating to Nonqualified Stock Options. 
 (ii) Exercise
Price. The Exercise Price of each Share covered by an Option shall be not less than 100% of the Fair Market Value of such Share (determined as of the date the Option is granted); provided, however, that in the case of an Incentive
Stock Option granted to an employee who, at the time of the grant of such Option, owns stock representing more than 10% of the voting power of all classes of stock of the Company or any Affiliate, the per Share Exercise Price shall be no less than
110% of the Fair Market Value per Share on the date of the grant. 
 (iii) Vesting and Exercise. Each Option shall be
vested and exercisable at such times, in such manner and subject to such terms and conditions as the Committee may, in its sole and plenary discretion, specify in the applicable Award Agreement or thereafter. Except as otherwise specified by the
Committee in the applicable Award Agreement, an 

  
 9 

 
Option may only be exercised to the extent that it has already vested at the time of exercise. Except as otherwise specified by the Committee in the Award Agreement, Options shall become vested
and exercisable with respect to one-third of the Shares subject to such Options on each of the first three anniversaries of the date of grant. An Option shall be deemed to be exercised when written or electronic notice of such exercise has been
given to the Company in accordance with the terms of the Award by the person entitled to exercise the Award and full payment pursuant to Section 6(b)(iv) for the Shares with respect to which the Award is exercised has been received by the
Company. Exercise of an Option in any manner shall result in a decrease in the number of Shares that thereafter may be available for sale under the Option and, except as expressly set forth in Section 4(c), in the number of Shares that may be
available for purposes of the Plan, by the number of Shares as to which the Option is exercised. The Committee may impose such conditions with respect to the exercise of Options, including, without limitation, any conditions relating to the
application of Federal or state securities laws, as it may deem necessary or advisable. 
 (iv) Payment.
(A) No Shares shall be delivered pursuant to any exercise of an Option until payment in full of the aggregate Exercise Price therefor is received by the Company, and the Participant has paid to the Company an amount equal to any Federal, state,
local and foreign income and employment taxes required to be withheld. Such payments may be made in cash (or its equivalent) or, in the Committee’s sole and plenary discretion, any other manner, including (1) by exchanging Shares owned by
the Participant (which are not the subject of any pledge or other security interest) or (2) if there shall be a public market for the Shares at such time, subject to such rules as may be established by the Committee, through delivery of
irrevocable instructions to a broker to sell the Shares otherwise deliverable upon the exercise of the Option and to deliver promptly to the Company an amount equal to the aggregate Exercise Price, or by a combination of the foregoing;
provided that the combined value of all cash and cash equivalents and the Fair Market Value of any such Shares so tendered to the Company as of the date of such tender is at least equal to such aggregate Exercise Price and the amount of any
Federal, state, local or foreign income or employment taxes required to be withheld. 
 (B) Wherever in the Plan or any Award
Agreement a Participant is permitted to pay the Exercise Price of an Option or taxes relating to the exercise of an Option by delivering Shares, the Participant may, subject to procedures satisfactory to the Committee, satisfy such delivery
requirement by presenting proof of beneficial ownership of such Shares, in which case the Company shall treat the Option as exercised without further payment and shall withhold such number of Shares from the Shares acquired by the exercise of the
Option. 
 (v) Expiration. Each Option shall expire at the time or times, and on the other terms and conditions, set
forth in the applicable Award Agreement, except that no Option may be exercisable after the tenth anniversary of the date the Option is granted. 
 (c) SARs. (i) Grant. Subject to the provisions of the Plan, the Committee shall have sole and plenary authority to determine the Participants to whom SARs shall be granted, the number
of Shares to be covered by each SAR, the Exercise Price thereof and the conditions and limitations applicable to the exercise thereof. SARs may be granted in 

  
 10 

 
tandem with another Award, in addition to another Award or freestanding and unrelated to another Award. SARs granted in tandem with, or in addition to, an Award may be granted either at the same
time as the Award or at a later time. 
 (ii) Exercise Price. The Exercise Price of each Share covered by a SAR shall be
not less than 100% of the Fair Market Value of such Share (determined as of the date the SAR is granted). 
 (iii)
Exercise. A SAR shall entitle the Participant to receive an amount equal to the excess, if any, of the Fair Market Value of a Share on the date of exercise of the SAR over the Exercise Price thereof. The Committee shall determine, in its sole
and plenary discretion, whether a SAR shall be settled in cash, Shares, other securities, other Awards, other property or a combination of any of the foregoing. 
 (iv) Other Terms and Conditions. Subject to the terms of the Plan and any applicable Award Agreement, the Committee shall determine, at or after the grant of a SAR, the vesting criteria, term,
methods of exercise, methods and form of settlement and any other terms and conditions of any SAR. Any such determination by the Committee may be changed by the Committee from time to time and may govern the exercise of SARs granted or exercised
thereafter. The Committee may impose such conditions or restrictions on the exercise of any SAR as it shall deem appropriate or desirable. 
 (v) Expiration. Each SAR shall expire at the time or times, and on the other terms and conditions, set forth in the applicable Award Agreement, except that no SAR may be exercisable after the tenth
anniversary of the date the SAR is granted. 
 (d) Restricted Shares and RSUs. (i) Grant. Subject to the
provisions of the Plan, the Committee shall have sole and plenary authority to determine the Participants to whom Restricted Shares and RSUs shall be granted, the number of Restricted Shares and RSUs to be granted to each Participant, the duration
of the period during which, and the conditions, if any, under which, the Restricted Shares and RSUs may vest or may be forfeited to the Company (the “Period of Restriction”) and the other terms and conditions of such Awards. Subject to
Section 3, no grant of Restricted Shares or RSUs shall become vested with respect to all the Restricted Shares or RSUs subject to such grant over a period that is shorter than three years after the date of grant; provided that Restricted
Shares or RSUs that are subject to performance-based vesting criteria, may become vested with respect to all the Restricted Shares or RSUs covered by the applicable grant over a period that is not shorter than one year after the date of grant.

 (ii) Transfer Restrictions. Restricted Shares and RSUs may not be sold, assigned, transferred, pledged or otherwise
encumbered except as provided in the Plan or as may be provided in the applicable Award Agreement; provided, however, that prior to vesting, Restricted Shares and RSUs may not be transferred. Certificates issued in respect of
Restricted Shares shall be registered in the name of the Participant and deposited by such Participant, together with a stock power endorsed in blank, with the Company or such other custodian as may be designated by the Committee or the Company, and
shall be held by the Company or other custodian, as applicable, until such time as the restrictions applicable to such Restricted Shares lapse. Upon the lapse of the restrictions applicable to such Restricted Shares, the Company or other custodian,
as applicable, shall deliver such certificates to the Participant or the Participant’s legal representative. 

  
 11 

 (iii) Payment/Lapse of Restrictions. Each RSU shall be granted with respect to one
Share or shall have a value equal to the Fair Market Value of one Share. RSUs shall be paid in cash, Shares, other securities, other Awards or other property, as determined in the sole and plenary discretion of the Committee, upon the lapse of
restrictions applicable thereto, or otherwise in accordance with the applicable Award Agreement. 
 (iv) Dividends and Other
Distributions. During the Period of Restriction, Participants holding Restricted Shares or RSUs granted hereunder may, as determined by the Committee or specified in the applicable Award Agreement, be paid or credited with (A) regular
dividends paid with respect to the Shares underlying the Restricted Shares while they are so held or (B) regular dividends paid with respect to the number of Shares equivalent to the number of RSUs while they are so held. Such dividends may, as
determined by the Committee or specified in the applicable Award Agreement, be credited with interest from the date of the dividends through the date of payment. The Committee may also apply any restrictions to the dividends that the Committee deems
appropriate and as are set forth in the Award Agreement. 
 (e) Performance Units. (i) Grant. Subject to the
provisions of the Plan, the Committee shall have sole and plenary authority to determine the Participants to whom Performance Units shall be granted and the terms and conditions thereof. 

(ii) Value of Performance Units. Each Performance Unit shall have an initial value that is established by the Committee at the
time of grant. The Committee shall set Performance Goals in its discretion which, depending on the extent to which they are met during a Performance Period, will determine the number and value of Performance Units that will be paid out to the
Participant. 
 (iii) Earning of Performance Units. Subject to the provisions of the Plan, after the applicable
Performance Period has ended, the holder of Performance Units shall be entitled to receive a payout of the number and value of Performance Units earned by the Participant over the Performance Period, to be determined by the Committee, in its sole
and plenary discretion, as a function of the extent to which the corresponding Performance Goals have been achieved. 
 (iv)
Form and Timing of Payment of Performance Units. Subject to the provisions of the Plan, the Committee, in its sole and plenary discretion, may pay earned Performance Units in the form of cash or in Shares (or in a combination thereof)
that has an aggregate Fair Market Value equal to the value of the earned Performance Units at the close of the applicable Performance Period. Such Shares may be granted subject to any restrictions in the applicable Award Agreement deemed appropriate
by the Committee. The determination of the Committee with respect to the form and timing of payout of such Awards shall be set forth in the applicable Award Agreement; provided, subject to Section 3, no grant of Performance Units shall
become vested with respect to all the Performance Units subject to such grant over a period that is shorter than one year after the date of grant. 
 (f) Other Stock-Based Awards. Subject to the provisions of the Plan, the Committee shall have the sole and plenary authority to grant to Participants other equity-based or equity-related Awards
(including, but not limited to, fully-vested Shares) in such amounts and subject to such terms and conditions as the Committee shall determine. Subject to Section 3, no grant of such awards shall become vested with respect to all the

  
 12 

 
awards subject to such grant over a period that is shorter than three years after the date of grant; provided that other equity-based or equity-related Awards that are subject to
performance-based vesting criteria, may become vested with respect to all the awards covered by the applicable grant over a period that is not shorter than one year after the date of grant. 

(g) Dividend Equivalents. In the sole and plenary discretion of the Committee, an Award, other than an Option or SAR, may provide
the Participant with dividends or dividend equivalents, payable in cash, Shares, other securities, other Awards or other property, on a current or deferred basis, on such terms and conditions as may be determined by the Committee in its sole and
plenary discretion, including, without limitation, payment directly to the Participant, withholding of such amounts by the Company subject to vesting of the Award or reinvestment in additional Shares, Restricted Shares or other Awards. 

SECTION 7. Amendment and Termination. (a) Amendments to the Plan. Subject to any applicable law or government
regulation, to any requirement that must be satisfied if the Plan is intended to be a shareholder approved plan for purposes of the rules of the NYSE or any successor exchange or quotation system on which the Shares may be listed or quoted, the
Plan may be amended, modified or terminated by the Board without the approval of the stockholders of the Company except that stockholder approval shall be required for any amendment that would (i) increase the maximum number of Shares for which
Awards may be granted under the Plan or increase the maximum number of Shares that may be delivered pursuant to Incentive Stock Options granted under the Plan; provided, however, that any adjustment under Section 4(b) shall
not constitute an increase for purposes of this Section 7(a), (ii) change the class of employees or other individuals eligible to participate in the Plan, or (iii) materially amend the Plan. No modification, amendment or termination
of the Plan may, without the consent of the Participant to whom any Award shall theretofor have been granted, materially and adversely affect the rights of such Participant (or his or her transferee) under such Award, unless otherwise provided by
the Committee in the applicable Award Agreement. 
 (b) Amendments to Awards. The Committee may waive any conditions or
rights under, amend any terms of, or alter, suspend, discontinue, cancel or terminate any Award theretofor granted, prospectively or retroactively; provided, however, that, except as set forth in the Plan, unless otherwise provided by the Committee
in the applicable Award Agreement, any such waiver, amendment, alteration, suspension, discontinuance, cancellation or termination that would materially and adversely impair the rights of any Participant or any holder or beneficiary of any Award
theretofor granted shall not to that extent be effective without the consent of the impaired Participant, holder or beneficiary. 
 (c) Adjustment of Awards Upon the Occurrence of Certain Unusual or Nonrecurring Events. The Committee is hereby authorized to make adjustments in the terms and conditions of, and the criteria
included in, Awards in recognition of unusual or nonrecurring events (including, without limitation, the events described in Section 4(b) or the occurrence of a Change of Control) affecting the Company, any Affiliate, or the financial
statements of the Company or any Affiliate, or of changes in applicable rules, rulings, regulations or other requirements of any governmental body or securities exchange, accounting principles or law (i) whenever the Committee, in its sole and

  
 13 

 
plenary discretion, determines that such adjustments are appropriate or desirable, including, without limitation, providing for a substitution or assumption of Awards, accelerating the
exercisability of, lapse of restrictions on, or termination of, Awards or providing for a period of time for exercise prior to the occurrence of such event, (ii) if deemed appropriate or desirable by the Committee, in its sole and plenary
discretion, by providing for a cash payment to the holder of an Award in consideration for the cancellation of such Award, including, in the case of an outstanding Option or SAR, a cash payment to the holder of such Option or SAR in consideration
for the cancellation of such Option or SAR in an amount equal to the excess, if any, of the Fair Market Value (as of a date specified by the Committee) of the Shares subject to such Option or SAR over the aggregate Exercise Price of such Option or
SAR and (iii) if deemed appropriate or desirable by the Committee, in its sole and plenary discretion, by canceling and terminating any Option or SAR having a per Share Exercise Price equal to, or in excess of, the Fair Market Value of a Share
subject to such Option or SAR without any payment or consideration therefor. 
 SECTION 8. Change of Control.
Unless otherwise provided in the applicable Award Agreement or any other agreement between the applicable Participant and the Company, in the event of a Change of Control after the date of the adoption of the Plan, unless provision is made in
connection with the Change of Control for (a) assumption of Awards previously granted or (b) substitution for such Awards of new awards covering stock of a successor corporation or its “parent corporation” (as defined in
Section 424(e) of the Code) or “subsidiary corporation” (as defined in Section 424(f) of the Code) with appropriate adjustments as to the number and kinds of shares and the Exercise Prices, if applicable, (i) any
outstanding Options or SARs then held by Participants that are unexercisable or otherwise unvested shall automatically be deemed exercisable or otherwise vested, as the case may be, as of immediately prior to such Change of Control, (ii) all
Performance Units shall be paid out as if the date of the Change of Control were the last day of the applicable Performance Period and “target performance levels” had been attained and (iii) all other outstanding Awards (including
Restricted Shares and RSUs) then held by Participants that are unexercisable, unvested or still subject to restrictions or forfeiture, shall automatically be deemed exercisable and vested and all restrictions and forfeiture provisions related
thereto shall lapse as of immediately prior to such Change of Control. 
 SECTION 9. General Provisions.
(a) Nontransferability. During the Participant’s lifetime, each Award (and any rights and obligations thereunder) shall be exercisable only by the Participant, or, if permissible under applicable law, by the Participant’s
legal guardian or representative, and no Award (or any rights and obligations thereunder) may be assigned, alienated, pledged, attached, sold or otherwise transferred or encumbered by a Participant otherwise than by will or by the laws of descent
and distribution, and any such purported assignment, alienation, pledge, attachment, sale, transfer or encumbrance shall be void and unenforceable against the Company or any Affiliate; provided that (i) the designation of a beneficiary
shall not constitute an assignment, alienation, pledge, attachment, sale, transfer or encumbrance and (ii) the Board or the Committee may permit further transferability, on a general or specific basis, and may impose conditions and limitations
on any permitted transferability; provided, however, that Awards cannot be transferred for consideration; provided further, however, that Incentive Stock Options 

  
 14 

 
granted under the Plan shall not be transferable in any way that would violate Section 1.422-2(a)(2) of the Treasury Regulations. All terms and conditions of the Plan and all Award
Agreements shall be binding upon any permitted successors and assigns. 
 (b) No Rights to Awards. No Participant or
other Person shall have any claim to be granted any Award, and there is no obligation for uniformity of treatment of Participants or holders or beneficiaries of Awards. The terms and conditions of Awards and the Committee’s determinations and
interpretations with respect thereto need not be the same with respect to each Participant and may be made selectively among Participants, whether or not such Participants are similarly situated. 

(c) Share Certificates. All certificates for Shares or other securities of the Company or any Affiliate delivered under the Plan
pursuant to any Award or the exercise thereof shall be subject to such stop transfer orders and other restrictions as the Committee may deem advisable under the Plan, the applicable Award Agreement or the rules, regulations and other requirements of
the SEC, NYSE or any other stock exchange or quotation system upon which such Shares or other securities are then listed or reported and any applicable Federal or state laws, and the Committee may cause a legend or legends to be put on any such
certificates to make appropriate reference to such restrictions. 
 (d) Withholding. (i) Authority to
Withhold. A Participant may be required to pay to the Company or any Affiliate, and the Company or any Affiliate shall have the right and is hereby authorized to withhold from any Award, from any payment due or transfer made under any Award or
under the Plan or from any compensation or other amount owing to a Participant, the amount (in cash, Shares, other securities, other Awards or other property) of any applicable withholding taxes in respect of an Award, its exercise or any payment or
transfer under an Award or under the Plan and to take such other action as may be necessary in the opinion of the Committee or the Company to satisfy all obligations for the payment of such taxes. 

(ii) Alternative Ways to Satisfy Withholding Liability. Without limiting the generality of clause (i) above, a
Participant may satisfy, in whole or in part, the foregoing withholding liability by delivery of Shares owned by the Participant (which are not subject to any pledge or other security interest and which have been owned by the Participant for at
least six months) having a Fair Market Value equal to such withholding liability or, at the discretion of the Company, by having the Company withhold from the number of Shares otherwise issuable pursuant to the exercise of the Option or SAR, or
the lapse of the restrictions on any other Awards (in the case of SARs and other Awards, if such SARs and other Awards are settled in Shares), a number of Shares having a Fair Market Value equal to such withholding liability. 

(e) Section 409A of the Code. Participants are solely responsible and liable for the satisfaction of all taxes and penalties
that may arise in connection with Awards (including any taxes arising under Section 409A of the Code), and the Company shall not have any obligation to indemnify or otherwise hold any participant harmless from any or all of such taxes. The
Committee shall have the discretion to organize any deferral program, to require deferral election forms, and to grant or to unilaterally modify any Award in a manner that (i) conforms with the requirements of Section 409A of the Code,
(ii) voids any Participant election to the extent it would violate Section 409A of the Code and 

  
 15 

 
(iii) for any distribution event or election that could be expected to violate Section 409A of the Code, make the distribution only upon the earliest of the first to occur of a
“permissible distribution event” within the meaning of Section 409A of the Code, or a distribution event that the participant elects in accordance with Section 409A of the Code. The Committee shall have the sole discretion to
interpret the requirements of the Code, including Section 409A, for purposes of the Plan and all Awards. 
 (f) Award
Agreements. Each Award hereunder shall be evidenced by an Award Agreement, which shall be delivered to the Participant and shall specify the terms and conditions of the Award and any rules applicable thereto, including, but not limited to,
the effect on such Award of the death, disability or termination of employment or service of a Participant and the effect, if any, of such other events as may be determined by the Committee. 

(g) No Limit on Other Compensation Arrangements. Nothing contained in the Plan shall prevent the Company or any Affiliate from
adopting or continuing in effect other compensation arrangements, which may, but need not, provide for the grant of options, restricted stock, shares and other types of equity-based awards (subject to stockholder approval if such approval is
required), and such arrangements may be either generally applicable or applicable only in specific cases. 
 (h) No Right to
Employment. The grant of an Award shall not be construed as giving a Participant the right to be retained as a director, officer, employee or consultant of or to the Company or any Affiliate, nor shall it be construed as giving a Participant any
rights to continued service on the Board. Further, the Company or an Affiliate may at any time dismiss a Participant from employment or discontinue any directorship or consulting relationship, free from any liability or any claim under the Plan,
unless otherwise expressly provided in the Plan or in any Award Agreement. 
 (i) No Rights as Stockholder. No
Participant or holder or beneficiary of any Award shall have any rights as a stockholder with respect to any Shares to be distributed under the Plan until he or she has become the holder of such Shares. Notwithstanding the foregoing, in connection
with each grant of Restricted Shares, except as provided in the applicable Award Agreement, the Participant shall be entitled to the rights of a stockholder (including the right to vote and receive dividends) in respect of such Restricted Shares.
Except as otherwise provided in Section 4(b), Section 7(c) or the applicable Award Agreement, no adjustments shall be made for dividends or distributions on (whether ordinary or extraordinary, and whether in cash, Shares, other
securities or other property), or other events relating to, Shares subject to an Award for which the record date is prior to the date such Shares are delivered. 
 (j) Governing Law. The validity, construction and effect of the Plan and any rules and regulations relating to the Plan and any Award Agreement shall be determined in accordance with the laws
of Bermuda, without giving effect to the conflict of laws provisions thereof. 
 (k) Severability. If any provision of
the Plan or any Award is or becomes or is deemed to be invalid, illegal or unenforceable in any jurisdiction or as to any Person or Award, or would disqualify the Plan or any Award under any law deemed applicable by the Committee, such provision
shall be construed or deemed amended to conform to the 

  
 16 

 
applicable laws, or if it cannot be construed or deemed amended without, in the determination of the Committee, materially altering the intent of the Plan or the Award, such provision shall be
construed or deemed stricken as to such jurisdiction, Person or Award and the remainder of the Plan and any such Award shall remain in full force and effect. 
 (l) Other Laws. The Committee may refuse to issue or transfer any Shares or other consideration under an Award if, acting in its sole and plenary discretion, it determines that the issuance or
transfer of such Shares or such other consideration might violate any applicable law or regulation or entitle the Company to recover the same under Section 16(b) of the Exchange Act, and any payment tendered to the Company by a
Participant, other holder or beneficiary in connection with the exercise of such Award shall be promptly refunded to the relevant Participant, holder or beneficiary. Without limiting the generality of the foregoing, no Award granted hereunder shall
be construed as an offer to sell securities of the Company, and no such offer shall be outstanding, unless and until the Committee in its sole and plenary discretion has determined that any such offer, if made, would be in compliance with all
applicable requirements of the U.S. Federal and any other applicable securities laws. 
 (m) No Trust or Fund Created.
Neither the Plan nor any Award shall create or be construed to create a trust or separate fund of any kind or a fiduciary relationship between the Company or any Affiliate, on one hand, and a Participant or any other Person, on the other hand. To
the extent that any Person acquires a right to receive payments from the Company or any Affiliate pursuant to an Award, such right shall be no greater than the right of any unsecured general creditor of the Company or such Affiliate. 

(n) No Fractional Shares. No fractional Shares shall be issued or delivered pursuant to the Plan or any Award, and the Committee
shall determine whether cash, other securities or other property shall be paid or transferred in lieu of any fractional Shares or whether such fractional Shares or any rights thereto shall be canceled, terminated or otherwise eliminated. 

(o) Requirement of Consent and Notification of Election Under Section 83(b) of the Code or Similar Provision. No
election under Section 83(b) of the Code (to include in gross income in the year of transfer the amounts specified in Section 83(b) of the Code) or under a similar provision of law (whether United States, United Kingdom or
otherwise) may be made unless expressly permitted by the terms of the applicable Award Agreement or by action of the Committee in writing prior to the making of such election. If an Award recipient, in connection with the acquisition of Shares under
the Plan or otherwise, is expressly permitted under the terms of the applicable Award Agreement or by such Committee action to make such an election and the Participant makes the election, the Participant shall notify the Committee of such election
within ten days of filing notice of the election with the IRS or other governmental authority, in addition to any filing and notification required pursuant to regulations issued under Section 83(b) of the Code or other applicable
provision. 
 (p) Requirement of Notification Upon Disqualifying Disposition Under Section 421(b) of the Code.
If any Participant shall make any disposition of Shares delivered pursuant to the exercise of an Incentive Stock Option under the circumstances described in Section 421(b) of the Code (relating to certain disqualifying dispositions) or any
successor provision of the Code, such Participant shall notify the Company of such disposition within ten days of such disposition. 
  

  
 17 

 (q) Headings. Headings are given to the Sections and subsections of the Plan solely
as a convenience to facilitate reference. Such headings shall not be deemed in any way material or relevant to the construction or interpretation of the Plan or any provision thereof. 

SECTION 10. Term of the Plan. (a) Effective Date. The Plan shall be effective as of the date of its
adoption by the Board and approval by the Company’s stockholders; provided, however, that no Incentive Stock Options may be granted under the Plan unless it is approved by the Company’s stockholders within twelve
(12) months before or after the date the Plan is adopted by the Board. 
 (b) Expiration Date. No Award shall be
granted under the Plan after the tenth anniversary of the date the Plan is approved under Section 10(a). Unless otherwise expressly provided in the Plan or in an applicable Award Agreement, any Award granted hereunder may, and the authority of
the Board or the Committee to amend, alter, adjust, suspend, discontinue or terminate any such Award or to waive any conditions or rights under any such Award shall, nevertheless continue thereafter. 

Approved: May 3, 2012 

  
 18Letter Agreement

 Exhibit 10.1 
 LV ADMINISTRATIVE SERVICES, INC. 
 as Administrative and Collateral Agent

 420 LEXINGTON AVENUE, SUITE 2840 
 NEW YORK, NY 10170 
 MAY 10, 2012 

Biovest International, Inc. 
 324 South Hyde Park
Avenue, Suite 350 
 Tampa, Florida 33606 
 Attn: Chief Executive Officer/President 
 Re: Sale and/or Repayment of Biovest
Term Notes 
 Ladies and Gentlemen: 
 Reference is made to: (a) that certain Term Loan & Security Agreement dated as of November 17, 2010 (as amended, supplemented, restated or modified from time to time, the “Term
Loan & Security Agreement”) by and between LV Administrative Services, Inc. (“LV”) as Agent for and on behalf of each of Laurus Master Fund, Ltd. (in liquidation) (“Laurus”), Erato Corporation
(“Erato”), Valens Offshore SPV I, Ltd. (“VOF”), Valens Offshore SPV II, Corp. (“VOF2”), Valens U.S. SPV I, LLC. (“VUS”), PSource Structured Debt Limited (“PSD”) and
the other creditor parties named therein from time to time (Laurus, Erato, VOF, VOF2, VUS, PSD and such other creditor parties, collectively, the “Lenders”) and Biovest International, Inc. (“Biovest”);
(b) Secured Term Notes A and B (the “Term Notes”) issued on or about November 17, 2010 to the Lenders; and (c) the Ancillary Agreements (as defined in the Term Loan & Security Agreement). Capitalized
terms used but not defined herein shall have the meanings ascribed thereto in the Term Loan & Security Agreement or the Ancillary Agreements, as applicable. 
 WHEREAS, as of November 17, 2010, (i) Laurus was issued 1,877,510 shares of Biovest common stock, (ii) VOF was issued 7,320,877, (iii) VUS was issued 1,036,468 shares of Biovest
common stock and (iv) PSD was issued 4,599,927 shares of Biovest common stock; and 
 WHEREAS, Biovest is seeking to
arrange for one or more purchaser(s), which may include a direct purchase by Biovest, to, acquire on or before August 15, 2012 the Term Notes and Term Loan & Security Agreement together with a large portion of the Biovest common stock
owned by certain of the Lenders and one-half of the BiovaxID Biologic Products Royalty owned by the Lenders for an aggregate purchase price of approximately $31 million; and 

WHEREAS, pursuant to Section 42 of the Term Loan & Security Agreement, LV has the authority to enter into this
Letter Agreement modifying, amending and waiving certain terms and provisions of the Term Loan & Security Agreement and the Ancillary Agreements, which action will constitute the valid and binding action on behalf of each of the Lenders,
subject to their acknowledgement and consent of same. 

  
 1 

 In consideration of good and valuable consideration, the receipt and sufficiency of which
are hereby acknowledged, Biovest and LV as designated Agent for and on behalf of the Lenders hereby agree to, and acknowledge, the following: 
  

	1.	SALE OF THE BIOVEST TERM NOTES. 

  

	 	A.	If on or before August 15, 2012 Biovest or its designee indefeasibly pays $30.9 million in cash to LV in purchase of the Term Notes (the “Buy Out
Amount”), (i) the Lenders shall assign to Biovest or its designee: (a) the Term Notes, and (b) the Term Loan & Security Agreement and all collateral securing the Term Notes, (ii) each of Laurus, VOF and VUS (Laurus,
VOF and VUS, collectively, the “LV Group”) shall assign an aggregate of 9,232,132 shares of common stock of Biovest owned by the LV Group as of the repayment date (the “LV Subject Common Stock”), (iii) PSD
shall assign 1,000,000 shares of common stock of Biovest owned by PSD as of the repayment date (the “PSD Subject Common Stock”) and (iv) one half of each of the Lenders ownership interest of the BiovaxID Biologic Products
Royalty representing in the aggregate a 3.125% Royalty (the “Subject Royalty”). For clarity the Lenders will retain in the aggregate a 3.125% Royalty and Biovest will acquire a 3.125% Royalty. 

 

	 	B.	Prior to August 15, 2012, the Lenders may only sell their shares of Biovest common stock in SEC Rule 144 market transactions, provided, that, the maximum number of
shares that may be sold is limited to 1% of the outstanding shares of Biovest or an aggregate of 1,454,881 shares (the “Lender Excluded Shares”). Subject to Clause D below, the above restriction in this Clause B shall not apply
after August 15, 2012. 

  

	 	C.	 If on or before August 15, 2012, Biovest fails to pay to LV the entire Buy Out Amount but Biovest does indefeasibly pay at least $20 million in
cash to LV in partial repayment of the outstanding principal balance of the Term Notes (such qualifying partial repayment, the “Minimum Paydown Amount”): (i) LV and the Lenders will agree to amend together with Biovest the Term
Notes such that: (a) the maturity date of the Term Notes will be extended to December 31, 2014; (b) the section providing a right to mandatory prepayment of the Term Notes (Section 4.4) may be deleted or otherwise modified by Biovest;
(c) the provisions of Section 2.2 regarding the right to be granted a certain number of seats on the Biovest Board upon certain events of default may be deleted or otherwise modified by Biovest and (ii) to the extent that the proceeds
of the Minimum Paydown Amount are derived from funds borrowed by Biovest from a third party lender (the “New Lender”) then, in such case: (a) Biovest may issue a note to such New Lender with a principal balance equal to the
aggregate amount of such borrowed money not to exceed the amount of the actual Minimum Paydown Amount paid to LV plus an additional $12 million maturing no earlier than December 31, 2014, (b) Biovest may also grant to such New Lender a
security interest in the same of Biovest’s assets which 

  
 2 

	 	
currently collateralize the Term Notes held by the Lenders and such new liens granted by Biovest for the benefit of the New Lender shall be deemed Permitted Liens under the Term Loan &
Security Agreement and the Ancillary Agreements, and (c) upon request LV, on behalf of the Lenders, shall negotiate and enter into with Biovest and such New Lender a pari passu inter-creditor agreement in form and substance mutually
acceptable to each of LV, the Lenders, Biovest and such New Lender such that the lien and payment priority of LV and the Lenders and such New Lender shall be pari passu; provided, that, no intervening security interests shall be permitted to
exist between those of LV, the Lenders and such New Lender at the time of negotiating such pari passu inter-creditor agreement; (iii) the LV Group will assign and transfer to Biovest or its designee(s) the percentage of the LV Subject
Common Stock equal to the amount of the Minimum Paydown Amount actually paid to LV divided by $30.9 million (For example: a repayment of $20 million would result in 65% of the LV Subject Common Stock (or 6,000,886 shares of the LV Subject Common
Stock being transferred to Biovest and 3,231,246 shares of the LV Subject Common Stock being retained by the LV Group) and as a second example a repayment of $25 million would result in 81% of the LV Subject Common Stock (or 7,478,027 shares of the
LV Subject Common Stock being transferred to Biovest and 1,754,105 shares of the LV Subject Common Stock being retained by the LV Group)); (iv) the PSD will assign and transfer to Biovest or its designee(s) the percentage of the PSD Subject
Common Stock equal to the amount of the Minimum Paydown Amount actually paid to LV divided by $30.9 million (For example: a repayment of $20 million would result in 65% of the PSD Subject Common Stock (or 650,000 shares of the PSD Subject Common
Stock being transferred to Biovest and 350,000 shares of the PSD Subject Common Stock being retained by PSD) and as a second example a repayment of $25 million would result in 81% of the PSD Subject Common Stock (or 810,000 shares of the PSD Subject
Common Stock being transferred to Biovest and 190,000 shares of the PSD Subject Common Stock being retained by PSD)); (v) the Lenders will assign and transfer to Biovest or its designee(s) the percentage of the Subject Royalty equal to the
amount of the Minimum Paydown Amount actually paid in cash to LV divided by $30.9 million and then multiplied by  1/2 (For example: a repayment of $20 million would result in 32% of the Subject Royalty being returned to Biovest and 68% of the Subject Royalty being retained by the Lenders (or 2.03%
of the 6.25% Subject Royalty being returned to Biovest and 4.22% of the 6.25% Subject Royalty being retained by the Lenders) and as a second example a repayment of $25 million would result in 40% of the Subject Royalty being returned to Biovest and
60% of the Subject Royalty being retained by the Lenders (or 2.53% of the 6.25% Subject Royalty being transferred to Biovest and 3.72% of the 6.25% Subject Royalty being retained by the Lenders) and (vi) if Biovest indefeasibly repays all of
the remaining principal and 

  
 3 

	 	
interest under the Term Notes within 90 days following the repayment of at least $20 million, the Lenders will transfer and assign to Biovest: (i) the Term Notes and all related
documentation thereto, (ii) additional royalty so that immediately following the transfer the Lenders will own in the aggregate one-half (or 3.125%) of the 6.25% Subject Royalty and Biovest will own one-half (or 3.125%) of the 6.25% Subject
Royalty and (ii) additional shares of Biovest common stock so that immediately following the transfer all of the LV Subject Common Stock (representing 9,232,132 shares) and all of the PSD Subject Common Stock (representing 1,000,000 shares)
will have been transferred to Biovest. During such 90 day period following the payment of the Minimum Paydown Amount on or prior to August 15, 2012, the Lenders will not sell any of the LV Subject Common Stock retained by the Lenders and PSD
will not sell any of the PSD Subject Common Stock retained by PSD. 

  

	 	D.	If on or before August 15, 2012, Biovest has an executed binding and enforceable commitment from a third party, subject to customary due diligence, document
preparation and other closing conditions for syndicated loans from U.S. chartered banking institutions, to fund the Minimum Paydown Amount or purchase of the Term Notes in their entirety, LV and the Lenders will grant a 45 day extension to permit
time for Biovest to close the transaction provided Biovest pays the interest accruing under the Term Notes on a monthly basis during the additional extension period. 

 

	 	E.	With respect to 3,000,000 shares of the total number of Biovest common stock held as of the date hereof by PSD (the “PSD Restricted Shares”), to the
extent that LV has received by or on behalf of PSource after the date hereof and on or before August 15, 2012, either the Buy Out Amount or the Minimum Paydown Amount, (i) PSD hereby agrees to enter into an Option and Lock Up Agreement in
the form attached hereto as Exhibit A (the “Lock-Up Agreement”) whereby, subject to the terms and conditions of such Lock-Up Agreement, the sale and/or assignment of the PSD Restricted Shares would be prohibited for a period
of two years from the date hereof (the “Lock-Up Period”), and (ii) during such Lock-Up Period, Biovest or its designee shall have the option to purchase all or any portion of the PSD Restricted Shares for a purchase price of
$0.50 per share in cash. 

  

	2.	MISCELLANEOUS. 

  

	 	A.	Biovest hereby represents and warrants to LV and the Lenders the following as a material inducement to LV and the Lenders to enter into this Letter Agreement:

 (i) Biovest has all requisite power and authority and full legal capacity to execute and deliver this Letter
Agreement and to perform its obligations hereunder; 

  
 4 

 (ii) Biovest is duly organized, validly existing and in good standing under the laws of the
state of Delaware; 
 (iii) all of Biovest’s representations and warranties set forth in the Term Notes, the Term
Loan & Security Agreement and each other Ancillary Agreement are true and correct as of the date hereof (or when given if expressly limited to a specific date), all covenant requirements set forth therein have been met and there current
does not exist any default or event of default under such documents and/or instruments; 
 (iv) The execution, delivery and
performance of this Letter Agreement by the undersigned on behalf of Biovest and the consummation of the transactions contemplated hereby by Biovest have been duly and validly authorized by all requisite action on the part of Biovest, and no other
proceedings on Biovest’s part are necessary to authorize the execution, delivery or performance of this Letter Agreement; and 
 (v) The execution, delivery and performance of this Letter Agreement by Biovest and the consummation of the transactions contemplated hereby do not conflict with or result in any material breach of,
constitute a material default under, result in a material violation of, result in the creation of any material lien, security interest, charge or encumbrance upon any material assets of Biovest (except as may be expressly contemplated herein), or
require any material authorization, consent, approval, exemption or other material action by or notice to any court, other governmental body or other third party, under the provisions of any material indenture, mortgage, lease, loan agreement or
other material agreement or instrument to which Biovest is bound, or any law, statute, rule or regulation or order, judgment or decree to which Biovest is subject. 
  

	 	B.	To the extent that each of the representations and warranties of Biovest set forth above are true and correct as of the date hereof, this Letter Agreement shall first
become effective as of the first date upon which (i) each of LV, the Lenders and Biovest shall have duly executed and exchanged their respective counterpart signatures to this Letter Agreement, (ii) Accentia Biopharmacueticals, Inc.
(“ABPI”) shall deliver to LV a duly authorized and executed reaffirmation and ratification agreement in form and substance satisfactory to LV which agreement shall reaffirm and ratify all of ABPI’s agreements and grants of
security to LV in relation to the obligations arising under the Term Notes as amended hereby and (iii) Corps Real LLC (or their assign), as senior lender to Biovest, shall consent to and acknowledge this Letter Agreement and further agree to
waive all claims against LV and the Lenders to collect from LV and/or any Lender any proceeds received by LV and/or the Lenders resulting from the purchase/assignment or repayment of the Term Notes as contemplated herein, such payments to LV and/or
the Lenders to be expressly permitted under the terms of that certain Subordination Agreement, dated as of November 17, 2010 by and between LV, Corps Real LLC and Biovest, as amended and restated from time to time. 

 

	 	C.	 Except as specifically amended herein, there are no other amendments, modifications or waivers to the Term Notes, the Term Loan & Security
Agreement or any other Ancillary Agreement, and all of the other forms, terms and provisions of the Term Notes, the Term Loan & Security Agreement and each other Ancillary Agreement shall remain in full

  
 5 

	 	
force and effect, and are hereby ratified and confirmed. The execution, delivery and effectiveness of this Letter Agreement shall not operate as a waiver of any right, power or remedy, nor
constitute a waiver of any provision of the Term Notes, the Term Loan & Security Agreement or any Ancillary Agreement except as otherwise provided herein. This Letter Agreement shall be binding upon and inure to the benefit of the parties
hereto and their respective heirs, executors, administrators, successors and assigns and shall be governed by and construed in accordance with the laws of the State of New York. 

 

	 	D.	If Biovest fails to purchase the Term Notes from the Lenders in their entirety or repay to LV the Minimum Paydown Amount on or before August 15, 2012 (or, subject
to satisfaction of the conditions set forth in Clause 1.D. above, within 45 days following August 15, 2012), this Letter Agreement shall automatically terminate and be of no continuing effect. 

 

	 	E.	This Letter Agreement may be executed by the parties hereto in one or more counterparts, each of which shall be deemed an original and all of which when taken together
shall constitute one and the same agreement. Any signature delivered by a party by facsimile or ‘pdf’ or other electronic transmission shall be deemed to be an original signature hereto. 

[Remainder of Page Intentionally Left Blank] 

  
 6 

 IN WITNESS WHEREOF, the parties hereto have executed this Letter Agreement as of the date
first set forth above. 
  

			
	Very truly yours,
	
	LV ADMINISTRATIVE SERVICES, INC., as administrative/collateral agent for the Lenders
		
	By:	 	 /s/ Eugene Grin

	Name:	 	Eugene Grin
	Title:	 	Authorized Signatory
	
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	 /s/ Samuel S. Duffey

	Name:	 	Samuel S. Duffey
	Title:	 	CEO and President

  

					
		  	7	  	

 
			
	ACKNOWLEDGED AND AGREED: LAURUS MASTER FUND, LTD. (IN LIQUIDATION)
		
	By:	 	 /s/ Russell Smith

	Name:	 	Russell Smith
	Title:	 	Authorized Signatory
	
	ERATO CORPORATION, by Laurus Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Eugene Grin

	Name:	 	Eugene Grin
	Title:	 	Authorized Signatory
	
	VALENS OFFSHORE SPV I, LTD., by Valens Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Eugene Grin

	Name:	 	Eugene Grin
	Title:	 	Authorized Signatory
	
	VALENS OFFSHORE SPV II, CORP., by Valens Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Eugene Grin

	Name:	 	Eugene Grin
	Title:	 	Authorized Signatory
	
	VALENS U.S. SPV I, LLC., by Valens Capital Management, LLC, its investment manager
		
	By:	 	 /s/ Eugene Grin

	Name:	 	Eugene Grin
	Title:	 	Authorized Signatory
	
	PSOURCE STRUCTURED DEBT LIMITED, by PSource Capital Limited, its investment consultant
		
	By:	 	 /s/ Soondra Apparoo

	Name:	 	Soondra Apparoo
	Title:	 	Managing Director

  

					
		  	8	  	

 EXHIBIT A 
 FORM OF OPTION AND LOCK-UP AGREEMENT 

  
 9 

 PSOURCE STRUCTURED DEBT LIMITED 

SARNIA HOUSE, LE TRUCHOT 
 ST PETER PORT. GUERNSEY, GY1 4NA 

                 , 201     

Biovest International, Inc. 
 324 South Hyde
Park Avenue, Suite 350 
 Tampa, Florida 33606 
 Attn: Chief Executive Officer/President 
  

	 	Re:	Biovest International, Inc. (the “Company”) 

 Gentlemen: 
 PSource Structured Debt Limited (“PSD”) is an owner
of record or beneficially of certain shares of common stock (“Common Stock”) of the Company. The Company proposes to enter into an amendment to: (i) the Term Loan & Security Agreement dated as of November 17, 2010
(as amended, supplemented, restated or modified from time to time, the “Term Loan & Security Agreement”) by and between LV Administrative Services, Inc. (“LV”) as Agent for and on behalf of each of Laurus
Master Fund, Ltd. (in liquidation) (“Laurus”), Erato Corporation (“Erato”), Valens Offshore SPV I, Ltd. (“VOF”), Valens Offshore SPV II, Corp. (“VOF2”), Valens U.S. SPV I, LLC.
(“VUS”), PSource Structured Debt Limited (“PSD”) and the other creditor parties named therein from time to time (Laurus, Erato, VOF, VOF2, VUS, PSD and such other creditor parties, collectively, the
“Lenders”); (ii) Secured Term Notes A and B (the “Term Notes”) issued on or about November 17, 2010 to the Lenders by the Company; and (iii) the Ancillary Agreements (as defined in the Term
Loan & Security Agreement) (the “Transaction”). PSD recognizes that the Transaction will be of benefit to PSD and will benefit the Company. PSD acknowledges that the Company is relying on the representations and agreements
of PSD contained in this letter agreement in carrying out the Transaction. 
 In consideration of the
foregoing and solely in respect of 3,000,000 shares of Common Stock currently owned either of record or beneficially by PSD (the “Restricted Common Stock”), PSD hereby agrees that it will not, without the prior written consent of
the Company, directly or indirectly, sell, offer, contract or grant any option to sell (including without limitation any short sale), pledge, transfer, establish an open “put equivalent position” within the meaning of Rule 16a-1(h) under
the Securities Exchange Act of 1934, as amended, or otherwise dispose of any shares (collectively, a “Transfer”) of the Restricted Common Stock currently owned either of record or beneficially (as defined in Rule 13d-3 under the
Securities Exchange Act of 1934, as amended) by PSD, or publicly announce an intention to do any of the foregoing, during the period (the “Restricted Period”) commencing on the date hereof and ending on
May     , 2014, subject to the exclusions and termination events otherwise described in this letter agreement. The restrictions as set forth in the immediately preceding sentence shall not apply to: (1) during the Restricted
Period the Transfer of any or all of the shares of Restricted Common Stock owned by PSD to any affiliate of PSD, liquidating trust (or another similarly purposed structure) the beneficiaries of which are PSD’s shareholders and/or investors or
any other party in a private sale transaction; provided, however, 

  

					
		  		  	

 
that it shall be a condition to such Transfer that the transferee executes and delivers to the Company an agreement stating that the transferee is receiving and holding the Restricted Common
Stock subject to the provisions of this letter agreement, and there shall be no further transfer of such Restricted Common Stock except in accordance with this letter agreement; and (ii) during the period commencing on the twelve (12) month
anniversary of the date hereof through the expiration of the Restricted Period, the Transfer of any or all of the shares of Restricted Common Stock owned by PSD to any other party; provided, that, PSD shall obtain the prior written
consent from the Company for each such proposed Transfer (which consent shall not be unreasonably withheld by the Company); provided, further, that, to the extent that the Company does not respond to a request for consent from
PSD within 5 business days of delivery thereof, consent to such proposed Transfer shall be deemed granted by the Company. Furthermore, to the extent and in the manner as described in clauses (i) through (iii) below, the Transfer
restrictions set forth above in this letter agreement shall be automatically terminated and of no further force or effect (each, a “Release”): 

(i) on the 90th day immediately following the date hereof (the “Partial Release Date”), a Release shall occur in
respect of that number of shares of the Restricted Common Stock determined by using the following formula (the
“90th Day Released Shares”): 
 X = 3,000,000 – (3,000,000 x (Y/$30,900,000)) 

X =    Number of shares of Restricted Common Stock to be released 

Y =    The aggregate amount of all repayments made by or on behalf of the Company of the outstanding principal
balance of the Term Notes and received by LV between May     , 2012 and the Partial Release Date. 
 For
example: a repayment of an aggregate amount of $20 million by the Partial Release Date would result in the release of approximately 35% of the Restricted Common Stock (or 1,058,253 shares of the Restricted Common Stock) from the Transfer
restrictions set forth in this letter agreement and as a second example a repayment of $25 million would result in the release of approximately 19% of the Restricted Common Stock (or 572,816 shares of the Restricted Common Stock) from the Transfer
restrictions set forth in this letter agreement. 
 ; and 

(ii) if a Trigger Event shall have occurred then, in such case, on the later to occur of the Partial Release Date and the date of
expiration of the Purchase Option Exercise Period (as defined below), a Release shall also occur in respect of those shares of Restricted Common Stock available for purchase by the Company from PSD pursuant to the terms of this letter agreement that
are not subject to a timely executed and delivered Purchase Option Notice (as defined below) hereunder (the “Additional Released Shares”); and 
 (iii) if a Trigger Event shall have occurred and a Purchase Option Notice delivered in accordance with the terms and conditions of this Agreement, on the date of expiration of the Closing Period (as
defined below) a Release shall occur in respect of all remaining shares of Restricted Common Stock not otherwise previously Released hereunder, and, at the sole option of PSD, all agreements related to a proposed Closing shall be automatically
terminated and have no further force or effect. 
 PSD also agrees and consents to the entry of stop transfer instructions with
the Company’s transfer agent and registrar against the transfer of shares of the Restricted Common Stock held by PSD except in compliance with the foregoing restrictions (subject to all exclusions and termination events as also described in
this letter agreement). 

  

					
		  	2	  	

 In the event that at any time during the Restricted Period, the average closing price of the
Common Stock (as reported by Bloomberg, L.P.) for twenty (20) consecutive trading days is greater than or equal to $1.25 per share at the end of each such day (the “Trigger Event” and, the last day of such Trigger Event, the
“Trigger Date”), PSD hereby grants to the Company, subject to the terms and conditions herein described, the right to purchase (the “Purchase Option”) from PSD for a cash purchase price of $0.50 per share in a
single transaction up to that number of shares of Restricted Common Stock as determined using the following formula (the “Maximum Available Share Formula”): 
 X = 3,000,000 x (Y/$30,900,000) 
 X =     Number of shares of
Restricted Common Stock available for purchased by the Company upon occurrence of Trigger Date. 
 Y =
    The aggregate amount of all repayments of the outstanding principal balance of the Term Notes made by or on behalf of the Company (and received by LV) between May     , 2012 and the Partial Release Date.

 For example: the occurrence of a Trigger Event and an aggregate repayment of $20 million by the Partial Release Date would
result in a Purchase Option right for up to approximately 65% of the Restricted Common Stock (or 1,941,747 shares of the Restricted Common Stock) and as a second example, the occurrence of a Trigger Event and an aggregate repayment of $25 million
would result in a Purchase Option right for up to approximately 81% of the Restricted Common Stock (or 2,427,184 shares of the Restricted Common Stock). 
 In the event that the Company wishes to exercise the Purchase Option, the Company shall deliver no later than the twentieth (20th) day following delivery of notice from PSD of the occurrence of the
Trigger Event (the “Purchase Option Exercise Period”), a notice (the “Purchase Option Notice”) to the offices of PSD c/o
                                        or such
other location designated in writing by PSD (with a copy to LV at
                                        or such
other location designated in writing by LV) setting forth (i) the proposed date of such exercise, and (ii) subject to the restriction imposed by the Maximum Available Share Formula, the number of shares of Restricted Common Stock subject
to such exercise of the Purchase Option. In the event that a Trigger Event occurs prior to the Partial Release Date, to the extent that the Company repays additional principal indebtedness under the Term Notes after expiration of the Purchase Option
Exercise Period and prior to the Partial Release Date, on the Partial Release Date the Company may revise upon written notice to PSD that number of shares of Restricted Common Stock subject to such Purchase Option exercise by recalculating the
Maximum Available Share Formula incorporating such additional repaid principal indebtedness. The closing for the exercise of the Purchase Option (the “Closing”) shall take place, and all cash payments from the Company to PSD shall
be delivered to LV, no later than one hundred (100) days following first receipt of a Purchase Option Notice (the “Closing Period”) at the offices of the PSD, or such other location designated in writing by PSD. At the Closing,
PSD shall deliver the applicable shares of Restricted Common Stock related to such Closing, deeds, assignments and other instruments of sale, assignment and transfer of the Restricted Common Stock related to such Closing (including, without
limitation, evidence of due authorization, execution and 

  

					
		  	3	  	

 
delivery of the instruments of transfer, evidence of title and the absence of any liens or competing claims) as the Company shall reasonably request to effectively transfer good and valid title
to the Restricted Common Stock related to such Closing. The Company shall pay any registration fees or other similar stamp or other taxes or fees payable or due upon the exercise of the Purchase Option and any such sale, assignment and/or transfer
related thereto. The Company hereby acknowledges that PSD beneficial owns or is owner of record of shares of Common Stock in addition to the Restricted Common Stock (the “Non-Restricted Common Stock”) and further agrees that the
restrictions set forth in this letter agreement do not apply to the Non-Restricted Common Stock (though other restrictions may from time to time apply under law or contract). 
 This Letter Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective heirs, executors, administrators, successors and assigns and shall be governed by and
construed in accordance with the laws of the State of New York. 
 This Letter Agreement may be executed by the parties hereto
in one or more counterparts, each of which shall be deemed an original and all of which when taken together shall constitute one and the same agreement. Any signature delivered by a party by facsimile or ‘pdf’ or other electronic
transmission shall be deemed to be an original signature hereto. 
 [Remainder of Page Intentionally Left Blank] 

  

					
		  	4	  	

 IN WITNESS WHEREOF, the parties hereto have executed this Letter Agreement as of the date
first set forth above. 
  

			
	 PSOURCE STRUCTURED DEBT LIMITED
 By: PSource Capital Limited, its investment consultant

		
	By:	 	  

	Name:	 	
	Title:	 	
	
	AGREED AND ACKNOWLEDGED:
	
	BIOVEST INTERNATIONAL, INC.
		
	By:	 	  

	Name:	 	
	Title:	 	

  

					
		  	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]